Skip to main content
SpringerLink
Log in

The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer

  • Original Paper
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Identification and characterization of the genetic background in patients with the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome is important since control programmes can in a cost-effective manner prevent cancer development in high-risk individuals. HNPCC is caused by germline mismatch repair (MMR) gene mutations and the genetic analysis of HNPCC therefore includes assessment of microsatellite instability (MSI) and immunohistochemical MMR protein expression in the tumor tissue. MSI is found in >95% of the HNPCC-associated tumors and immunostaining using antibodies against the MMR proteins MLH1, MSH2, and MSH6 has been found to correctly pinpoint the affected gene in about 90% of the cases. The PMS2 antibody was the most recently developed and we have in a clinical material assessed the added value of PMS2 immunostaining in 213 patients with suspected hereditary colorectal cancer. All 119 MSS tumors showed retained expression for all four antibodies and PMS2 did thus not identify any underlying MMR defect in these cases. However, PMS2 immunostaining contributed to the characterization of the MMR defect in a subset of the MSI tumors. Concomitant loss of MLH1 and PMS2, which functionally interact in the MutLα complex, was found in 98% of the tumors from patients with germline MLH1 mutations. Among the 12 MSI-high tumors with retained expression of MLH1, MSH2 and MSH6, 8 tumors showed loss of PMS2 staining, and mutations in MLH1 were identified in 2 and mutations in PMS2 in 3 of these individuals. In summary, isolated loss of PMS2 was found in 8% of the MSI-high tumors in our series, including 8/12 previously unexplained MSI-high tumors, in which mutations either in MLH1 or in PMS2 were identified in five cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Watson P, Lynch HT (2001) Cancer risk in mismatch repair gene mutation carriers. Fam Cancer 1:57–60

    Article  CAS  PubMed  Google Scholar 

  2. Hampel H, Stephens JA, Pukkala E, et’al. (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421

    Article  PubMed  Google Scholar 

  3. Leach FS, Nicolaides NC, Papadopoulos N, et’al. (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215–1225

    Article  CAS  PubMed  Google Scholar 

  4. Bronner CF, Baker SM, Morison PT, et’al. (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368:258–261

    Article  CAS  PubMed  Google Scholar 

  5. Papadopoulos N, Nicolaides NC, Wei YF, et’al. (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625–1629

    Article  CAS  PubMed  Google Scholar 

  6. Miyaki M, Konishi M, Tanaka K, et’al. (1997) Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 17:271–272

    Article  CAS  PubMed  Google Scholar 

  7. Peltomäki P, Vasen HF (2003) Mutations associated with HNPCC predisposition—update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20:269–276

    Google Scholar 

  8. Hamilton SR, Liu B, Parsons RE, et’al. (1995) The molecular basis of Turcot's syndrome. N Engl J Med 332:839–847

    Google Scholar 

  9. Worthely DL, Walsh MD, Barker M, et’al. (2005) Familial mutations in PMS2 can cause autosomal dominant hereditary nonpolyposis colorectal cancer. Gastroenterology 128:1431–1436

    Article  Google Scholar 

  10. Gryfe R, Gallinger S (2005) Germline PMS2 mutations: one hit or two? Gastroenterology 128:1506–1515

    Article  CAS  PubMed  Google Scholar 

  11. Hendriks YM, Jagmohan-Changur S, van der Klift HM, et’al. (2006) Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal cancer. Gastroenterology 130:312–322

    Article  CAS  PubMed  Google Scholar 

  12. Boland CR, Thibodeau SN, Hamilton SR, et’al. (1998) A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58:5248–5257

    CAS  PubMed  Google Scholar 

  13. Moslein G, Tester DJ, Lindor NM, et’al. (1996) Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Hum Mol Genet 5:1245–1252

    Article  CAS  PubMed  Google Scholar 

  14. Lindor NM, Burgart LJ, Leontovich O, et’al. (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20:1043–1048

    Article  CAS  PubMed  Google Scholar 

  15. Ruszkiewicz A, Bennett G, Moore J, et’al. (2002) Correlation between mismatch repair gene immunohistochemistry and microsatellite instability status in HNPCC-associated tumours. Pathology 34:541–546

    CAS  PubMed  Google Scholar 

  16. Rigau V, Sebbagh M, Olschwang S, et’al. (2003) Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 immunostaining. Arch Pathol Lab Med 127:694–700

    CAS  PubMed  Google Scholar 

  17. Halvarsson B, Lindblom A, Rambech E, et’al. (2004) Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer. Virchows Arch 444:135–141

    Article  CAS  PubMed  Google Scholar 

  18. Shia J, Ellis NA, Klimstra DS (2004) The utility of immunohistochemical detection of DNA mismatch repair gene proteins. Virchows Arch 445:431–441

    Article  CAS  PubMed  Google Scholar 

  19. Kolodner RD, Marsischky GT (1999) Eukaryotic DNA mismatch repair. Curr Opin Dev 9:89–96

    Article  CAS  Google Scholar 

  20. Umar A, Boland RC, Terdiman JP, et’al. (2004) Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J␣Natl Cancer Inst 96:261–268

    Article  CAS  PubMed  Google Scholar 

  21. Vasen HF, Watson P, Mecklin J-P, et’al. (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology 116:1453–1456

    Article  CAS  PubMed  Google Scholar 

  22. Clendenning M, Hampel H, LaJeunesse J, et’al. Long-range PCR facilitates the identification of PMS2 specific mutations. Hum Mutat, 2006; 27:490–495

    Google Scholar 

  23. Aaltonen LA, Salovara R, Kristo P, et’al. (1998) Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338:1481–1487

    Article  CAS  PubMed  Google Scholar 

  24. Hampel H, Frankel WL, Martin E, et’al. (2005) Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352:1851–1860

    Article  CAS  PubMed  Google Scholar 

  25. Järvinen HJ, Aarnio M, Mustonen H, et’al. (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834

    Article  PubMed  Google Scholar 

  26. Liljegren A, Lindgren G, Brandberg Y, et’al. (2004) Individuals with an increased risk of colorectal cancer: perceived benefits and psychological aspects of surveillance by means of regular colonoscopies. J Clin Oncol 22:1736–1742

    Article  CAS  PubMed  Google Scholar 

  27. Gritz ER, Peterson SK, Vernon SW, et’al. (2005) Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 23:1902–1910

    Article  PubMed  Google Scholar 

  28. Vasen HF, van Ballegooijen M, Buskens E, et’al. (1998) A cost-effectiveness analysis of colorectal screening of hereditary nonpolyposis colorectal carcinoma gene carriers. Cancer 82:1632–1637

    Article  CAS  PubMed  Google Scholar 

  29. Gill S, Lindor NM, Burgart LJ, et’al. (2005) Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. Clin Cancer Res 11:6466–6471

    Article  CAS  PubMed  Google Scholar 

  30. de Jong A, van Puijenbrock M, Hendriks Y, et’al. (2004) Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10:972–980

    Article  PubMed  Google Scholar 

  31. Engel C, Forberg J, Holinski-Feder F, et’al. (2006) Novel strategy for optimal sequential application of clinical criteria, immunhistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 118:115–122

    Article  CAS  PubMed  Google Scholar 

  32. Muller W, Burgart LJ, Krause-Paulus R, et’al. (2001) The reliability of immunohistochemistry as a pre-screening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)—results of an international collaborative study. Fam Cancer 1:87–93

    Article  CAS  PubMed  Google Scholar 

  33. Truninger K, Menigatti M, Luz J, et’al. (2005) Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer. Gastroenterology 128:1160–1171

    Article  CAS  PubMed  Google Scholar 

  34. Southey MS, Mark A, Jenkins LM, et’al. (2005) Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 20:6524–6532

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Financial support was granted from the Swedish Cancer society, the G Nilsson Cancer Fund, the B Kamprad Cancer Fund, the King Gustaf V Fund, and the Lund University Hospital Cancer Funds.

Author information

Authors and Affiliations

  1. Department of Pathology, Institute of Clinical Sciences, Lund University Hospital, Lund, Sweden

    Britta Halvarsson

  2. Department of Clinical Genetics, Institute of Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden

    Annika Lindblom & Kristina Lagerstedt

  3. Department of Oncology, Institute of Clinical Sciences, Lund University Hospital, Lund, Sweden

    Eva Rambech & Mef Nilbert

  4. Britta Halvarsson, Department of Pathology, Helsingborg Hospital, 251 87 Helsingborg, Sweden

    Britta Halvarsson

Authors
  1. Britta Halvarsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annika Lindblom
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eva Rambech
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kristina Lagerstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mef Nilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Britta Halvarsson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halvarsson, B., Lindblom, A., Rambech, E. et al. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer. Familial Cancer 5, 353–358 (2006). https://doi.org/10.1007/s10689-006-0005-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-006-0005-9

Keywords

Search

Navigation